Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
NCT01248117
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
DRUG:
ranibizumab 2.0mg
Sponsor
Retina Consultants of Hawaii
Collaborators
[object Object]